COVID-Globulin / Rostec - LARVOL DELTA

Development and characterization of anti-SARS-CoV-2 intravenous immunoglobulin from COVID-19 convalescent plasma. (PubMed, Immunotherapy) - "Intravenous anti-COVID-19 hyperimmune immunoglobulin protected immunosuppressed hamsters against SARS-Cov-2. The obtained results can allow the start of clinical trials to study the safety and efficacy in healthy adults."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Clinical Study in the Treatment of Patients With Moderate Course of COVID-19 (clinicaltrials.gov) - P2/3; N=376; Recruiting; Sponsor: Microgen; Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease

Rostec develops unique medication for coronavirus treatment (Saudi Gazette) - "The Russian Ministry of Health recently registered COVID Globulin — the world's first medication based on a coronavirus-specific immunoglobulin....The medication was registered upon submission of successful results of the pre-clinical trials and Stage 1 of clinical trials, which demonstrated its safety, absence of side effects, and the ability to neutralize the new coronavirus. The Registration Certificate approves the use of COVID Globulin for patients aged from 18 to 60....Moscow Health Department transferred to Rostec (Nacimbio) 2.5 tons of donor plasma and now provides venues to conduct Stage 2 and Stage 3 of the clinical trials...Stages 2 and 3 of the clinical trials will take about six months. Currently, COVID Globulin is intended for use only in Moscow hospitals participating in the trials — for medium or strong cases."

Non-US regulatory • Infectious Disease • Novel Coronavirus Disease